A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate single IV doses of Vestipitant (GW597599) compared to 4 mg IV
ondansetron for treating breakthrough postoperative nausea and vomiting (PONV) after failure
of PONV prophylaxis with a regimen that includes 4 mg IV ondansetron.